Datopotamab Deruxtecan: A New ADC Option for EGFR-Mutated NSCLC

This segment focuses on the recent FDA approval of datopotamab deruxtecan and its significance in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC). Panelists will discuss how this antibody–drug conjugate (ADC) differs from existing EGFR-directed therapies, particularly tyrosine kinase inhibitors, by leveraging targeted delivery of a cytotoxic payload to tumor cells expressing TROP2. The conversation will highlight the key clinical data that supported regulatory approval, including efficacy outcomes in patients with previously treated EGFR-mutated disease and the ability of this approach to address resistance to prior targeted therapies. Safety considerations and practical implications for sequencing will also be explored.